SI2099784T1 - 1,5-difenil-3-piridinilamino-1,5-dihidrorirolidin-2-oni kot modulatorji receptorja cb1 - Google Patents
1,5-difenil-3-piridinilamino-1,5-dihidrorirolidin-2-oni kot modulatorji receptorja cb1Info
- Publication number
- SI2099784T1 SI2099784T1 SI200731118T SI200731118T SI2099784T1 SI 2099784 T1 SI2099784 T1 SI 2099784T1 SI 200731118 T SI200731118 T SI 200731118T SI 200731118 T SI200731118 T SI 200731118T SI 2099784 T1 SI2099784 T1 SI 2099784T1
- Authority
- SI
- Slovenia
- Prior art keywords
- dihydrioyrrolidin
- pyridinylamino
- diphenyl
- ones
- receptor modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86254006P | 2006-10-23 | 2006-10-23 | |
EP07871196A EP2099784B1 (en) | 2006-10-23 | 2007-10-22 | 1,5-diphenyl-3-pyridinylamino-1,5-dihydrioyrrolidin-2-ones as cb1 receptor modulators |
PCT/US2007/082041 WO2008070305A2 (en) | 2006-10-23 | 2007-10-22 | 1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as cbl' receptor modulator |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2099784T1 true SI2099784T1 (sl) | 2013-02-28 |
Family
ID=39386481
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200731118T SI2099784T1 (sl) | 2006-10-23 | 2007-10-22 | 1,5-difenil-3-piridinilamino-1,5-dihidrorirolidin-2-oni kot modulatorji receptorja cb1 |
SI200730538T SI2094684T1 (sl) | 2006-10-23 | 2007-10-22 | 1,5-difenil-3-benzilamino-1,5-dihidropirolidin-2-oni kot modulatorji receptorjev cb1 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200730538T SI2094684T1 (sl) | 2006-10-23 | 2007-10-22 | 1,5-difenil-3-benzilamino-1,5-dihidropirolidin-2-oni kot modulatorji receptorjev cb1 |
Country Status (23)
Country | Link |
---|---|
US (2) | US7998985B2 (sl) |
EP (2) | EP2094684B1 (sl) |
JP (2) | JP5331002B2 (sl) |
KR (2) | KR101088236B1 (sl) |
CN (2) | CN101528732B (sl) |
AR (1) | AR063497A1 (sl) |
AT (1) | ATE492543T1 (sl) |
AU (1) | AU2007329808B2 (sl) |
BR (1) | BRPI0717347A2 (sl) |
CA (2) | CA2667372C (sl) |
CL (1) | CL2007003002A1 (sl) |
CY (1) | CY1111140T1 (sl) |
DE (1) | DE602007011495D1 (sl) |
DK (2) | DK2094684T3 (sl) |
EA (2) | EA015175B1 (sl) |
ES (2) | ES2398388T3 (sl) |
MX (2) | MX2009004053A (sl) |
PE (1) | PE20080926A1 (sl) |
PL (2) | PL2099784T3 (sl) |
PT (2) | PT2099784E (sl) |
SI (2) | SI2099784T1 (sl) |
TW (1) | TW200825067A (sl) |
WO (2) | WO2008070306A2 (sl) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR063497A1 (es) * | 2006-10-23 | 2009-01-28 | Lilly Co Eli | Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento |
DK2280961T3 (da) * | 2008-04-22 | 2012-08-27 | Lilly Co Eli | 1,5-diphenyl-pyrrolidin-2-on-forbindelser som cb-1-ligander |
JP5539322B2 (ja) * | 2008-04-22 | 2014-07-02 | イーライ リリー アンド カンパニー | Cb−1リガンドとしての1,5−ジフェニル−ピロリジン−2−オン化合物 |
WO2010057000A2 (en) * | 2008-11-13 | 2010-05-20 | The Trustees Of Columbia University In The City Of New York | Neuraminidase inhibitors and uses thereof |
BR112013000841A2 (pt) * | 2010-07-15 | 2016-06-07 | Oleg Lliich Epshtein | composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano. |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
WO2022132803A1 (en) * | 2020-12-14 | 2022-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Cb2 receptor agonists |
WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
US20230414598A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
DK1725536T3 (da) | 2004-02-19 | 2009-02-16 | Solvay Pharm Bv | Imidazolin-derivater med CB1-antagonistisk aktivitet |
US20060035245A1 (en) * | 2004-04-20 | 2006-02-16 | Ason Brandon L | Modulators of enzymatic nucleic acid elements mobilization |
WO2007020502A2 (en) * | 2005-08-16 | 2007-02-22 | Pharmacia & Upjohn Company Llc | Cannabinoid receptor ligands and uses thereof |
AR063497A1 (es) * | 2006-10-23 | 2009-01-28 | Lilly Co Eli | Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento |
-
2007
- 2007-10-18 AR ARP070104628A patent/AR063497A1/es unknown
- 2007-10-18 CL CL200703002A patent/CL2007003002A1/es unknown
- 2007-10-18 TW TW096139051A patent/TW200825067A/zh unknown
- 2007-10-18 PE PE2007001418A patent/PE20080926A1/es not_active Application Discontinuation
- 2007-10-22 WO PCT/US2007/082042 patent/WO2008070306A2/en active Application Filing
- 2007-10-22 PT PT78711967T patent/PT2099784E/pt unknown
- 2007-10-22 BR BRPI0717347-4A2A patent/BRPI0717347A2/pt not_active IP Right Cessation
- 2007-10-22 CN CN2007800394497A patent/CN101528732B/zh not_active Expired - Fee Related
- 2007-10-22 CN CN2007800394514A patent/CN101528733B/zh not_active Expired - Fee Related
- 2007-10-22 SI SI200731118T patent/SI2099784T1/sl unknown
- 2007-10-22 PL PL07871196T patent/PL2099784T3/pl unknown
- 2007-10-22 DK DK07871197.5T patent/DK2094684T3/da active
- 2007-10-22 AU AU2007329808A patent/AU2007329808B2/en not_active Ceased
- 2007-10-22 KR KR1020097008214A patent/KR101088236B1/ko not_active IP Right Cessation
- 2007-10-22 PL PL07871197T patent/PL2094684T3/pl unknown
- 2007-10-22 ES ES07871196T patent/ES2398388T3/es active Active
- 2007-10-22 EP EP07871197A patent/EP2094684B1/en not_active Not-in-force
- 2007-10-22 CA CA2667372A patent/CA2667372C/en not_active Expired - Fee Related
- 2007-10-22 DE DE602007011495T patent/DE602007011495D1/de active Active
- 2007-10-22 WO PCT/US2007/082041 patent/WO2008070305A2/en active Application Filing
- 2007-10-22 ES ES07871197T patent/ES2356025T3/es active Active
- 2007-10-22 EA EA200970405A patent/EA015175B1/ru not_active IP Right Cessation
- 2007-10-22 CA CA2667210A patent/CA2667210C/en not_active Expired - Fee Related
- 2007-10-22 MX MX2009004053A patent/MX2009004053A/es active IP Right Grant
- 2007-10-22 SI SI200730538T patent/SI2094684T1/sl unknown
- 2007-10-22 PT PT07871197T patent/PT2094684E/pt unknown
- 2007-10-22 EP EP07871196A patent/EP2099784B1/en not_active Not-in-force
- 2007-10-22 US US12/444,692 patent/US7998985B2/en not_active Expired - Fee Related
- 2007-10-22 AT AT07871197T patent/ATE492543T1/de active
- 2007-10-22 DK DK07871196.7T patent/DK2099784T3/da active
- 2007-10-22 MX MX2009004054A patent/MX2009004054A/es active IP Right Grant
- 2007-10-22 JP JP2009533586A patent/JP5331002B2/ja not_active Expired - Fee Related
- 2007-10-22 EA EA200970404A patent/EA015745B1/ru not_active IP Right Cessation
- 2007-10-22 JP JP2009533585A patent/JP5331001B2/ja not_active Expired - Fee Related
- 2007-10-22 KR KR1020097008216A patent/KR101088229B1/ko not_active IP Right Cessation
- 2007-10-22 US US12/441,570 patent/US8168659B2/en not_active Expired - Fee Related
-
2011
- 2011-01-27 CY CY20111100093T patent/CY1111140T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL198990A0 (en) | Cb1 receptor modulators | |
GB0623101D0 (en) | Secure network architecture | |
IL201973A0 (en) | 3,3-spiroindolinone derivatives | |
IL225694A0 (en) | Compounds 6,5- dihydro-h1-pyridine-2-one | |
ZA201001797B (en) | 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives | |
SI2094684T1 (sl) | 1,5-difenil-3-benzilamino-1,5-dihidropirolidin-2-oni kot modulatorji receptorjev cb1 | |
IL191767A0 (en) | Imidazoles as gaba-b receptor modulators | |
SI2356123T1 (sl) | Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni | |
GB0701992D0 (en) | Grehlin Receptor Modulators | |
ZA201004828B (en) | Cannabinoid receptor modulators | |
IL188388A0 (en) | Pyrazole derivatives as cb1 modulators | |
EP2097410A4 (en) | HETEROYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | |
GB0616467D0 (en) | Network tunnelling | |
GB0622569D0 (en) | Cannabinoid receptor modulators | |
ZA200806237B (en) | Cannibinoid receptor modulators | |
AU2008207290A8 (en) | Stirrup | |
DE602006020489D1 (de) | Cb1-rezeptormodulatoren | |
IL194972A0 (en) | 2-alkoxy-3,4,5-trihydroxy-alkylamide- | |
GB0811212D0 (en) | CB1 Receptor Modulators | |
ZA200904663B (en) | CB1 receptor modulators | |
GB0719111D0 (en) | T.m.2 | |
GB0724096D0 (en) | Cannabinoid receptor modulators | |
GB0623399D0 (en) | Receptor | |
GB0623853D0 (en) | Receptor | |
GB0608516D0 (en) | Receptor |